Harpoon Therapeutics, Inc. (HARP)
| Market Cap | 778.52M |
| Revenue (ttm) | 12.19M |
| Net Income (ttm) | -52.82M |
| Shares Out | 25.08M |
| EPS (ttm) | -2.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $23.70 |
| Previous Close | $24.16 |
| Change ($) | -0.47 |
| Change (%) | -1.92% |
| Day's Open | 24.11 |
| Day's Range | 23.60 - 24.91 |
| Day's Volume | 102,341 |
| 52-Week Range | 10.74 - 24.91 |
Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...
Underwriters Fully Exercise Option to Purchase Additional Shares Underwriters Fully Exercise Option to Purchase Additional Shares
Harpoon (HARP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of ...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, an...
HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development
Harpoon Therapeutics presents an opportunity in the cancer treatment space, and at the current levels, the stock is a good buy. HPN424, HARP's most advanced product, targets prostate cancer, w...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today present...
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced tod...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, to...
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...
Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board
SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...
Initiation of the clinical trial triggers $50 million milestone payment from AbbVie Initiation of the clinical trial triggers $50 million milestone payment from AbbVie
SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
The American Society of Clinical Oncology's annual meeting -- one of the most important healthcare industry gatherings of the year -- will happen without face-to-face contact.
Harpoon Therapeutics, Inc. (HARP) CEO Gerald McMahon on Q4 2019 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Harpoon Therapeutics, Inc. (HARP).
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year
HPN328, a TriTAC®, Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, ...
Tag along on two of them -- but watch out for this biotech upstart, on which Wall Street might be a little early.
About HARP
Harpoon Therapeutics, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; H... [Read more...]
| Industry Biotechnology | IPO Date Feb 8, 2019 |
| CEO Gerald McMahon | Employees 77 |
| Stock Exchange NASDAQ | Ticker Symbol HARP |
Financial Performance
In 2019, HARP's revenue was $5.78 million, an increase of 21.62% compared to the previous year's $4.75 million. Losses were -$55.57 million, 103.1% more than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for HARP stock is "Strong Buy." The 12-month stock price forecast is 31.89, which is an increase of 34.59% from the latest price.